Key Events This Week
Mar 2: Stock hits 52-week low at Rs.1,152.05
Mar 4: Gradual recovery with 0.44% gain
Mar 5: Technical momentum shifts with 1.45% rise
Mar 6: Week closes at Rs.1,262.00, up 0.43% for the week

Jupiter Life Line Hospitals Ltd is Rated Sell
2026-03-06 10:11:01Jupiter Life Line Hospitals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Read full news article
Jupiter Life Line Hospitals Ltd Technical Momentum Shifts Amid Mixed Market Returns
2026-03-06 08:03:00Jupiter Life Line Hospitals Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.45%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other trend analyses. This article delves into the detailed technical parameters and market context to provide investors with a comprehensive understanding of the stock’s current positioning.
Read full news article
Jupiter Life Line Hospitals Ltd Falls to 52-Week Low Amidst Continued Downtrend
2026-03-02 13:10:31Jupiter Life Line Hospitals Ltd has touched a new 52-week low of Rs.1152.05 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors. The stock has underperformed its sector and key benchmarks over the past year, reflecting a challenging period for the hospital sector player.
Read full news article
Jupiter Life Line Hospitals Ltd is Rated Sell
2026-02-23 10:10:51Jupiter Life Line Hospitals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news article









